Compare Cassava Sciences Inc (FLNA) vs Occidental Petroleum Corporation (OXY) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Occidental Petroleum (OXY) trades at $58.21, showing slight daily weakness but maintaining a bullish technical trend with strong fundamental metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.40 significantly exceeding the $1.83 forecast. Valuation remains attractive with a P/E of 17.78 and EV/EBITDA of 5.56, while profitability metrics show robust margins and returns.

OXY presents compelling value with analyst consensus price target of $71.40 representing 23% upside potential. The company's debt reduction progress and strong cash flow generation support dividend sustainability. Key risks include oil price volatility and execution challenges in carbon management initiatives. Wall Street sentiment remains positive with 52% buy ratings among analysts.